Please use this identifier to cite or link to this item:
|Title:||Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369: Mini-assessment Report|
|Assignee:||Medical Services Advisory Committee|
|Judy Morona and Ruchi Mittal|
|Abstract:||This contracted mini assessment examines the evidence to the support listing of 68Gallium-1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid-peptide (68Ga-DOTA-peptide) positron emission tomography (PET) / computed tomography (CT) scanning for the diagnosis of gastroenteropancreatic neuroendocrine tumours (GEP NETs) on the Medicare Benefits Schedule (MBS). The target population are people with clinically suspected GEP NETs. The applicant has claimed that the successful listing of the technology in the target population and setting will lead to a reduction in the number of repeated tests and superior safety in terms of faster acquisition time and lower radiation exposure. A systematic literature review was not undertaken for this mini-assessment; and therefore, the evidence base is incomplete. No comparative studies were identified to inform on therapeutic efficacy or effectiveness|
|Rights:||© Commonwealth of Australia 2017. This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney-General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at http://www.ag.gov.au/.|
|Appears in Collections:||Public Health publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.